ReviewCurrent osteoporosis reports2015
IL-6 and IGF-1 Signaling Within and Between Muscle and Bone: How Important is the mTOR Pathway for Bone Metabolism?
Review in Current osteoporosis reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 57 citations in OpenAlex.
- ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis.Molecular genetics and genomics : MGG · 2026Article
- The Rising Burden of Osteosarcopenia in Older Adults: A Narrative Review of Pathophysiology, Diagnostic Challenges, and Therapeutic Perspectives.Health science reports · 2026Article
- The Dual Role of Interleukin-6 in the Pathophysiology of Skeletal Muscle: Mechanisms, Challenges, and Therapeutic Prospects.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Research progress on the effects of macrophage‑derived exosomes on muscle factors IGF‑1 and FGF‑2 mediating musculoskeletal crosstalk molecular signaling pathway on bone metabolism (Review).International journal of molecular medicine · 2026Review
- Immunometabolic mechanisms of osteosarcopenic obesity: chronic inflammation, trained immunity, and systemic immune dysregulation.Frontiers in immunology · 2026Review
- Association between appendicular skeletal muscle index and bone turnover markers and bone mineral density in postmenopausal osteoporotic women.Archives of osteoporosis · 2025Article
- Slo1 Deficient Myoblast Exosomes-Derived miR-222-3p Inhibits Osteogenic Differentiation via Targeting of STAT3.Journal of cachexia, sarcopenia and muscle · 2025Article
- The role of GH/IGF-1 axis dysfunction and inflammatory cytokines in pediatric short stature.Journal of medical biochemistry · 2025Article
- Observational
- Inhibition of SFRP1 by microRNA‑206‑3p may be the underlying cause of osteosarcopenia.Biomedical reports · 2025Article
- Osteosarcopenia in older adults undergoing transcatheter aortic valve replacement: A narrative review of mortality and frailty implications.World journal of cardiology · 2025Review
- Recent advances in the multifaceted mechanisms of catalpol in treating osteoporosis.Frontiers in pharmacology · 2025Review
- Physical Exercise and the Gut Microbiome: A Bidirectional Relationship Influencing Health and Performance.Nutrients · 2024Review
- Effect of Single Session of Swedish Massage on Circulating Levels of Interleukin-6 and Insulin-like Growth Factor 1.International journal of molecular sciences · 2024Article
- MyD88 in osteoclast and osteoblast lineages differentially controls bone remodeling in homeostasis and malaria.International immunology · 2024Article
- Review
- Chitosan and Sodium Hyaluronate Hydrogels Supplemented with Bioglass for Bone Tissue Engineering.Gels (Basel, Switzerland) · 2024Article
- Review
- The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.Frontiers in immunology · 2024Review
- Differential expression of circular RNAs in interleukin 6-promoted osteogenic differentiation of human stem cells from apical papilla.Clinical oral investigations · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor 1 (IGF-1) and interleukin 6 (IL-6) play an important role in the adaptation of both muscle and bone to mechanical stimuli. Here, we provide an overview of the functions of IL-6 and IGF-1 in bone and muscle metabolism, and the intracellular signaling pathways that are well known to mediate these functions. In particular, we discuss the Akt/mammalian target of rapamycin (mTOR) pathway which in skeletal muscle is known for its key role in regulating the rate of mRNA translation (protein synthesis). Since the role of the mTOR pathway in bone is explored to a much lesser extent, we discuss what is known about this pathway in bone and the potential role of this pathway in bone remodeling. We will also discuss the possible ways of influencing IGF-1 or IL-6 signaling by osteocytes and the clinical implications of pharmacological or nutritional modulation of the Akt/mTOR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.